

North Central Cancer Treatment Group

N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ)
Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed
Glioblastoma

Status Change – December 31, 2008

NOTICE OF STATUS CHANGE

This study will temporarily close to accrual effective immediately
Wednesday, December 31, 2008 for safety assessment per study design.

Please retain this notice with the protocol.